Last reviewed · How we verify
Quetiapine 600mg
Quetiapine 600mg is a atypical antipsychotic Small molecule drug developed by AstraZeneca. It is currently FDA-approved.
Quetiapine is an atypical antipsychotic that acts as a serotonin and dopamine receptor antagonist.
Quetiapine 600mg, marketed by AstraZeneca, is an atypical antipsychotic used primarily for the treatment of schizophrenia and bipolar disorder. It works by modulating dopamine and serotonin receptors in the brain, helping to stabilize mood and reduce psychotic symptoms. Despite its efficacy, quetiapine has a range of side effects, including somnolence, dizziness, and weight gain, which can impact patient adherence. The drug is also under investigation for additional indications, such as major depressive disorder. Safety concerns include warnings about increased mortality in elderly patients with dementia-related psychosis.
At a glance
| Generic name | Quetiapine 600mg |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | atypical antipsychotic |
| Target | ["serotonin 5-HT2A receptors", "dopamine D2 receptors"] |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Mechanism of action
Quetiapine exerts its therapeutic effects by blocking serotonin and dopamine receptors, which helps to reduce psychotic symptoms and stabilize mood.
Approved indications
Pipeline indications
Boxed warnings
- Increased mortality in elderly patients with dementia-related psychosis
Common side effects
- somnolence
- dizziness
- weight gain
- dry mouth
- constipation
- tachycardia
- hypertension
Drug interactions
- CYP3A4 inhibitors (e.g., ketoconazole) may increase quetiapine levels
- CYP3A4 inducers (e.g., carbamazepine) may decrease quetiapine levels
Key clinical trials
- Quetiapine for Bipolar Disorder and Alcohol Dependence (PHASE4)
- Tolerance and Effect of Antipsychotics in Children and Adolescents With Psychosis (PHASE4)
- A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room (PHASE4)
- Quetiapine Sr as Adjunctive Treatment In Mixed States of Bipolar Disorder (PHASE4)
- Brexpiprazole in Patients With Acute Schizophrenia (PHASE3)
- Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia. (PHASE3)
- Neurophysiologic Changes in Patients With Bipolar Depression (PHASE4)
- A Study of Quetiapine for the Treatment of Mood Disorders in Adolescents (PHASE3)
Patents
| Patent | Expiry | Type |
|---|---|---|
| US5006528A | 2021 | |
| US5229382A | 2022 |
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Quetiapine 600mg CI brief — competitive landscape report
- Quetiapine 600mg updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Quetiapine 600mg
What is Quetiapine 600mg?
How does Quetiapine 600mg work?
Who makes Quetiapine 600mg?
What drug class is Quetiapine 600mg in?
What development phase is Quetiapine 600mg in?
What are the side effects of Quetiapine 600mg?
What does Quetiapine 600mg target?
Related
- Drug class: All atypical antipsychotic drugs
- Target: All drugs targeting ["serotonin 5-HT2A receptors", "dopamine D2 receptors"]
- Manufacturer: AstraZeneca — full pipeline
- Therapeutic area: All drugs in Neuroscience
- Compare: Quetiapine 600mg vs similar drugs
- Pricing: Quetiapine 600mg cost, discount & access